Status:
COMPLETED
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Compatibility of the topotecan therapy in combination with carboplatin.
Detailed Description
The aim of the study was to confirm the tolerability of 3-day topotecan therapy in combination with carboplatin in accordance with published data and to investigate the tolerability of continued thera...
Eligibility Criteria
Inclusion
- Age \>= 18 years
- patient with ovarian cancer after primary therapy
- bone marrow function leukocytes \>= 4,0 x 109/ l, platelets \>= 100 109/l, hemoglobin \>= 9 g/dl
- renal function creatinin \<= 1,5 mg% or creatinin clearance \>= 60 ml/min
- liver function bilirubin \<= 2,0 mg/dl, SGOT, SGPT and AP within 3 fold of the reference laboratory's normal range
- ECOG \<= 2
- Intention of regular follow-up visits for the duration of the study
- written informed consent
Exclusion
- any known hypersensitivity against topotecan isomerase-I-inhibitor other medication included in the study protocol
- ECOG \> 2
- patients with radiotherapy within the last 4 weeks
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00170625
Start Date
June 1 2004
Last Update
November 12 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.